Clinical AdvancementsAura Biosciences is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate (VDC) technology.
Financial PositionThe company has $151 million in cash and cash equivalents, providing financial runway into the second half of 2026.
Pipeline ProgressThe Phase 3 CoMpass trial in early-stage choroidal melanoma remains on track, with over 220 patients globally registered, indicating strong advancement in their pipeline.